No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

RAD Technology Medical Systems to Provide VRCC Veterinary Specialty and Emergency Hospital with Standalone Radiotherapy Center

Editor: What To Know

  • This facility originally served as a Temporary Radiotherapy Vault, or RAD Temp, and was previously used by cancer centers from coast to coast, in five states and the District of Columbia, to treat patients while those cancer centers upgraded their radiotherapy equipment.
  • RAD Technology Medical Systems (RAD) is pleased to announce that they will be providing Veterinary Referral Center of Colorado, also know as, VRCC Veterinary Specialty and Emergency Hospital (VRCC) in Sheridan, CO with a veterinary radiotherapy center.
  • Unlike with conventionally built radiotherapy centers, RAD’s facility and equipment will be able to make Beam within 5-7 days of its arrival on site, and will be ready to treat patients within 30 days of arrival.

RAD Technology Medical Systems (RAD) is pleased to announce that they will be providing Veterinary Referral Center of Colorado, also know as, VRCC Veterinary Specialty and Emergency Hospital (VRCC) in Sheridan, CO with a veterinary radiotherapy center. This facility will allow VRCC to provide improved radiation therapy treatment to animals with cancer.

RAD’s patented technology and offsite modular construction methods provide their customers with a flexible, high-quality facility solution that is completed ahead of conventional construction.

RAD’s modular radiotherapy center was the perfect solution for the growing VRCC. They were looking for a quick solution that would allow them to upgrade their services in the region. They selected a pre-existing RAD facility that will be updated and expanded to meet all of their specific program needs.

Unlike with conventionally built radiotherapy centers, RAD’s facility and equipment will be able to make Beam within 5-7 days of its arrival on site, and will be ready to treat patients within 30 days of arrival.

This facility originally served as a Temporary Radiotherapy Vault, or RAD Temp, and was previously used by cancer centers from coast to coast, in five states and the District of Columbia, to treat patients while those cancer centers upgraded their radiotherapy equipment.

“We are excited to be entering the Veterinary Market,” said Kenneth Wright, RAD’s Vice President of Sales and Business Development. “The veterinary oncology market is growing and our modular approach is the perfect solution for veterinary offices looking to expand or add radiation treatment to their location.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy